Reports Q3 revenue $1.58B, consensus $1.56B. “In 2024 our commercial execution has been very strong. Our largest product, Nexplanon, is well positioned to deliver $1 billion of revenue next year and we’ve added other notable growth drivers with Emgality and most recently, VTAMA,” said Kevin Ali, Organon’s (OGN) Chief Executive Officer. “Further, we have been extremely disciplined on operating costs and driving Adjusted EBITDA growth in support of achieving $1 billion of free cash flow before one-time costs for full year 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN:
- Organon, Shanghai Henlius Biotech: FDA accepts BLA for HLX14
- Organon completes acquisition of Dermavant
- Organon, Henlius announce Phase 3 study of HLX11 met primary endpoint
- Eyes on Fed ahead of expected interest rate cut: Morning Buzz
- Organon likely won’t lose money on deal with Roivant, says Evercore ISI